
Exact Sciences Corporation EXAS
$ 101.56
0.05%
Quarterly report 2025-Q3
added 11-03-2025
Exact Sciences Corporation General and Administrative Expenses 2011-2025 | EXAS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Exact Sciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 191 M | 196 M | 663 M | 801 M | 481 M | 540 M | 296 M | 186 M | 138 M | 106 M | 65.2 M | 22.7 M | 14.4 M | 8.14 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 801 M | 8.14 M | 265 M |
Quarterly General and Administrative Expenses Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 241 M | 209 M | 221 M | - | 194 M | 178 M | 220 M | - | 217 M | 238 M | 217 M | - | 192 M | 182 M | 170 M | - | 187 M | 168 M | 268 M | - | 116 M | 107 M | 114 M | 144 M | 80.5 M | 63.7 M | 63.8 M | 56.3 M | 46.7 M | 39.5 M | 35.5 M | 33.6 M | 30.8 M | 24.6 M | 20.1 M | 21.5 M | 20.3 M | 17.3 M | 17.8 M | 15.9 M | 15.4 M | 13.7 M | 13 M | 10.6 M | 8.99 M | 6.23 M | 4.59 M | 3.69 M | 3.69 M | 3.63 M | 2.65 M | 2.82 M | 2.55 M | 2.39 M | 2.14 M | 2.21 M | 1.95 M | 1.83 M | 2.15 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 268 M | 1.83 M | 79.1 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
5.78 M | $ 17.15 | 1.06 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 15.92 | 1.08 % | $ 171 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.58 | -2.78 % | $ 2.01 M | ||
|
DarioHealth Corp.
DRIO
|
18.1 M | $ 12.15 | 2.14 % | $ 345 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
1.19 B | $ 66.09 | -1.3 % | $ 25.5 B | ||
|
Castle Biosciences
CSTL
|
200 M | $ 38.69 | 0.16 % | $ 1.07 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
7.76 B | $ 227.19 | 0.3 % | $ 166 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 27.03 | -0.41 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
118 M | $ 19.92 | -3.11 % | $ 1.07 B | ||
|
Celcuity
CELC
|
9.06 M | $ 102.11 | -2.99 % | $ 4.03 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
7.44 M | $ 3.31 | -7.68 % | $ 106 K | ||
|
Co-Diagnostics
CODX
|
14.3 M | $ 0.31 | -9.31 % | $ 9.1 M | ||
|
IQVIA Holdings
IQV
|
1.99 B | $ 223.83 | 0.72 % | $ 40.6 B | ||
|
Guardant Health
GH
|
180 M | $ 103.97 | 1.86 % | $ 12.8 B | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.09 B | $ 134.95 | 0.06 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
751 M | $ 197.68 | 2.44 % | $ 10.2 B | ||
|
Quotient Limited
QTNT
|
37.4 M | - | -11.32 % | $ 1.1 M | ||
|
Mettler-Toledo International
MTD
|
936 M | $ 1 409.44 | 1.11 % | $ 29.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 183.97 | 0.8 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
80.5 M | $ 7.67 | -2.29 % | $ 995 M | ||
|
NeoGenomics
NEO
|
260 M | $ 12.13 | 2.32 % | $ 1.54 B | ||
|
Neogen Corporation
NEOG
|
218 M | $ 6.82 | -0.66 % | $ 1.48 B | ||
|
Myriad Genetics
MYGN
|
276 M | $ 7.03 | -2.57 % | $ 637 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 262.25 | -0.73 % | $ 22 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 185.36 | -0.65 % | $ 15.3 B | ||
|
IDEXX Laboratories
IDXX
|
442 M | $ 699.6 | -0.65 % | $ 57.7 B | ||
|
Lantheus Holdings
LNTH
|
194 M | $ 66.88 | 0.38 % | $ 4.63 B | ||
|
Agilent Technologies
A
|
1.62 B | $ 140.28 | 0.44 % | $ 42.6 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.42 | -5.19 % | $ 5.56 M | ||
|
Bioventus
BVS
|
304 M | $ 7.52 | -0.46 % | $ 471 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
170 M | $ 2.12 | - | $ 538 M | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K |